1. Scrip
  2. >>R&D
  3. >>Clinical Trials

WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention

Longer-Term MARIPOSA Results For J&J’s EGFR Drug Combo

 
• By Mandy Jackson

Highlights will include data for Summit/Akeso’s PD-L1/VEGF bispecific versus Keytruda, ADCs and DLL3-targeting drugs for SCLC, and agents against EGFR, HER2 and Trop-2 in NSCLC.

Holographic concept of lung cancer display, lung disease, treatment of lung cancer, lung illness
The WCLC starts on 7 September in San Diego • Source: Shutterstock

The International Association for the Study of Lung Cancer’s World Conference on Lung Cancer from 7 to 10 September in San Diego will showcase the increased focus on targeted therapies, including rising interest in bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs), in lung cancers.

Key Takeaways

  • The World Conference on Lung Cancer (WCLC) meeting 7-10 September in San Diego will highlight new directions in treatment, including antibody-drug conjugates and bispecifics.

  • AstraZeneca/Daiichi Sankyo’s TROP2-targeting ADC Dato-DXd will have multiple readouts in non-small cell lung cancer ahead of its potential second-line approval in the US in late 2024

The approval of Amgen, Inc.’s DLL3-targeting BiTE Imdelltra (tarlatamab) in small-cell lung cancer (SCLC) and the pending US Food and Drug Administration approval decision for AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Trop-2-targeting ADC datopotomab deruxtecan (Dato-DXd) in non-small cell lung cancer (NSCLC), due by 20 December, are prime examples of changes happening in the treatment landscape

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from R&D

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.